Search
Shark liver oil
go.drugbank.com/drugs/DB11088ApprovedShark oil is extracted from the livers of sharks, which can account for up to 25% of their total body weight. … However the major component is considered to be squalene, which may range up to 90% of the shark oil, depending on the species.
Mirikizumab
go.drugbank.com/drugs/DB14910ApprovedInvestigational[L46252] It was officially approved in the EU in May 2023[L48656] and Canada in July 2023[L48661], and was eventually approved in the US in October 2023[L48651] for the treatment of adult patients with … [L46237] In April 2023, the US FDA declined to approve mirikizumab for the treatment of ulcerative colitis on the basis of manufacturing concerns.
Penpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigationalThe use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events. … [A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998]
Categories: Programmed Death Receptor-1 Blocking AntibodyMitapivat
go.drugbank.com/drugs/DB16236ApprovedInvestigationalMitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. … [A245478] On January 5, 2026, the FDA also approved the use of in the treatment of anemia in adults with alpha- or beta-thalassemia, making it the first oral treatment for this condition.[L54953]
Synonyms: Pkr-in-1Asciminib
go.drugbank.com/drugs/DB12597ApprovedInvestigational[A241065] Asciminib is unique in that it acts as an allosteric inhibitor, binding at the myristoyl pocket of the BCR-ABL1 protein and locking it into an inactive conformation. … More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995] which serves as a driver of CML proliferation in most patients with the disease.
Rivaroxaban
go.drugbank.com/drugs/DB06228ApprovedInvestigationalRivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. … However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food.
Finerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigational[A236544] Spironolactone has low selectivity and affinity for the receptor; it dissociates quickly and can also have effects at the androgen, progesterone, and glucocorticoid receptors. … Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart
Categories: Mineralocorticoid Receptor Antagonists, Nonsteroidal Mineralocorticoid-Receptor AntagonistAldo-keto reductase family
go.drugbank.com/bio_entities/BE0009802EnzymeHumansCatalyzes the reduction of estrone into 17beta-estradiol but with low efficiency (PubMed:14672942). … Can form 17beta-hydroxysteroids such as testosterone and estradiol albeit with lower efficiency when compared to AKR1C3 (PubMed:10998348).
Synonyms: Estradiol 17-beta-dehydrogenase AKR1B15Rilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigational[L53743] ITP is an autoimmune disorder characterized by low platelet count. … Rilzabrutinib is thought to work by dual mechanisms of action in ITP: It attenuates macrophage (Fcγ receptor)-mediated platelet destruction and reduces the production of pathogenic autoantibodies.
Biotin
go.drugbank.com/drugs/DB00121ApprovedInvestigationalNutraceuticalA water-soluble, enzyme co-factor present in minute amounts in every living cell. It occurs mainly bound to proteins or polypeptides and is abundant in liver, kidney, pancreas, yeast, and milk.
Mixtures: Stress Formula Multivitamin Tablets USP, Adeks - DpsProducts: Tk-nax